Business Context and Reporting Period
This Form 8-K filing by Pacific Biosciences of California, Inc. (the "Company") reports on events occurring on February 13, 2018, with the report dated February 15, 2018. The filing primarily addresses the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 12,500,000 shares of common stock.
- Offering Price: $2.40 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 1,875,000 shares.
- Net Proceeds: Approximately $28.5 million (after deducting underwriting discounts and estimated offering expenses).
- Underwriter: Cantor Fitzgerald & Co., as representative of the several underwriters.
- Closing Date: February 15, 2018.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels as this is a current report focused on a capital raise event rather than a periodic financial statement.
Material Changes
The primary material change is the increase in the Company's share count and cash liquidity resulting from the public offering. The Company entered into an underwriting agreement to sell 12.5 million shares, significantly altering its capital structure compared to the prior period.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary regarding future operational outlook. The document notes that the Underwriting Agreement contains customary representations, warranties, and indemnification provisions. It explicitly states that the agreement is not intended to provide factual information about the Company beyond the terms of the transaction and that representations were made solely for the benefit of the parties to the agreement.
Key Facts for Investor Verification
- Verify the final closing of the offering and whether the 1,875,000 share over-allotment option was exercised.
- Confirm the exact net proceeds received after all offering expenses are finalized.
- Review the Company's most recent 10-K or 10-Q to assess liquidity needs and how these proceeds impact the balance sheet.
- Check for any subsequent filings regarding the use of proceeds or changes in capitalization.